Company Information

  

Address: 343 OYSTER POINT BLVD #200  
City: SOUTH SAN FRANCISCO 
State: CA 
Zip Code: 94080 
Telephone: 650-870-1000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage bio-pharmaceutical company focused on fighting cancer by discovering and developing novel small molecule oncology drugs that target tumor and immune cell metabolism. Tumor metabolism and immuno-oncology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. With our unique oncometabolism approach, we have discovered two small molecule drug candidates that are currently in clinical development. These agents take advantage of the unique metabolic requirements of tumor cells and cancer-fighting immune cells. Our lead product candidate, CB-839, is an internally discovered, first-in-class oral inhibitor of glutaminase, a critical enzyme in tumor cells. Our strategy is to develop CB-839 as combination therapy with approved agents, in order to improve the treatment of patients with cancer.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-0.93NAN/E
03/2018-0.99NAN/E
12/2017-0.84NAN/E
09/2017-0.98NAN/E
06/2017-1.24NAN/E
03/2017-1.65NAN/E
12/2016-1.95NAN/E
09/2016-1.95NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.09Total Liab/Total Assets0.22
Net Inc/Total Assets-0.14Total Liab/Inv Cap0.27
Net Inc/Inv Cap-0.18Total Liab/Comm Equity0.14
Pretax Inc/Net Sales-1.07Interest Coverage RatioNA
Net Inc/Net Sales-1.07Curr Debt/EquityNA
Cash Flow/Net Sales0.53LTD/EquityNA
SG&A/NetSales0.48Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover45.46Quick Ratio4.30
Inventory TurnoverNACurrent Ratio4.30
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.20Inv/Curr AssetsNA
Net Sales/PP&E14.76  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 17.07 5.19 7.25 7.25
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.50 3.51 3.30 3.07
Operating Income -3.74 -13.81 -11.54 -6.65
Interest Exp NA NA NA NA
Pretax Income -3.08 -13.21 -10.97 -6.07
Other Income 0.66 0.61 0.57 0.58
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -3.08 -13.21 -10.97 -6.07

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 141.41 150.96 163.79 165.61
Receivables - Total 2.51 1.82 1.14 2.18
Inventories - Total NA NA NA NA
Total Current Assets 145.44 155.81 167.67 172.05
Net Property, Plant & Equipment 1.63 1.66 1.76 1.37
Total Assets 158.98 178.58 192.46 205.54
Liabilities        
Accounts Payable 10.65 12.53 10.01 8.41
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 10.65 29.59 39.03 37.42
Long-Term Debt NA NA NA NA
Total Liabilities 11.81 30.72 42.15 47.45
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA 0.00 NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -157.82 -154.75 -150.33 -139.36
Treasury Stock NA NA NA NA
Total Stockholders' Equity 147.17 147.87 150.31 158.09
Total Liabilities and Stockholders' Equity 158.98 178.58 192.46 205.54

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -19.44 -14.95 -11.36 -11.31
Net Cash Provided by Investing Activities 20.09 21.17 18.66 -7.90
Net Cash Provided by Financing Activities 0.38 0.15 1.77 0.22

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-12.38--
12/20140.00-21.71-4.67
12/20150.00-32.64-1.81
12/20160.00-38.00-1.95
12/201725.96-27.83-0.84
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1811920,43656.79




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.